What is the significance of the villus-to-crypt ratio in duodenal or jejunal biopsies of an adult with combined immunodeficiency presenting with chronic diarrhea?

Villus-to-Crypt Ratio in Combined Immunodeficiency with Chronic Diarrhea

In an adult with combined immunodeficiency presenting with chronic diarrhea, a villus-to-crypt ratio below 3:1 indicates villous atrophy and signals a critical diagnostic finding that demands immediate investigation for opportunistic infections, immunoglobulin replacement, and urgent referral for hematopoietic stem cell transplantation. 1, 2

Normal Villus-to-Crypt Ratio and Pathologic Thresholds

• The normal villus-to-crypt ratio is 3:1 or greater in properly oriented duodenal biopsies 1
• A ratio below 3:1 indicates partial villous atrophy, while a ratio approaching 0 represents total villous atrophy 1
• Proper tissue orientation by an experienced laboratory technician is essential for accurate assessment, as misoriented biopsies cannot be reliably evaluated 1

Critical Significance in Combined Immunodeficiency

Villous Atrophy as a Marker of Severe Disease

• Villous atrophy in combined immunodeficiency patients with chronic diarrhea correlates with occult opportunistic infections in approximately 50% of cases, including Mycobacterium avium-intracellulare and microsporidia 3
• Patients with villous atrophy and identified occult infections demonstrate significantly greater weight loss (mean 14.3 kg vs 6.2 kg) and markedly reduced survival compared to those without identified pathogens 3
• The absence of plasma cells in the lamina propria alongside villous atrophy strongly suggests common variable immunodeficiency 1

Pathophysiology in Immunodeficiency

• Villous atrophy in HIV and combined immunodeficiency results from crypt stem cell and transit cell hyperproliferation, with increased mitotic activity predominantly in transit cells but also in stem cells 4
• This hyperproliferation causes crypt hypertrophy and encroachment of crypt cells onto villi, mechanically producing villous atrophy 4
• The architectural changes occur independent of diarrhea presence but correlate with T-cell dysfunction and subnormal epithelial proliferation in response to injury 3

Differential Diagnosis Beyond Celiac Disease

Common Variable Immunodeficiency Pattern

• Villous blunting under capsule endoscopy may be an endoscopic feature of primary immunodeficiency-related enteropathy in both CVID and X-linked agammaglobulinemia 5
• The histologic triad of villous atrophy, absent/reduced plasma cells in lamina propria, and chronic diarrhea with malabsorption points toward CVID 1, 5

Infectious Etiologies to Exclude

• Microsporidia (Enterocytozoon bieneusi, Encephalitozoon intestinalis) cause villous atrophy with elevated fecal TNF-α and respond to thalidomide therapy 6
• Giardiasis, tropical sprue, and HIV enteropathy all produce scalloped duodenal folds and reduced villus-to-crypt ratios 7
• Obtain at least 4-6 properly oriented biopsies from the second portion of duodenum and duodenal bulb to maximize detection of pathogens 1, 8

Autoimmune Enteropathy

• Presents with villous blunting, cryptitis with apoptosis, and scattered intraepithelial lymphocytes 9
• Distinguished by anti-enterocyte and anti-goblet cell antibodies and response to corticosteroid therapy 9

Essential Histologic Features to Report

The pathology report must include 1:

• Number and orientation of biopsies (including duodenal bulb specimens)
• Architectural features: normal, partial, subtotal, or total villous atrophy
• Villus height-to-crypt depth ratio (normal ≥3:1)
• Lamina propria cellular content: specifically note presence or absence of plasma cells, as their absence suggests common variable immunodeficiency
• Crypt hyperplasia presence
• Intraepithelial lymphocyte (IEL) count: normal is <25 IELs per 100 enterocytes 1, 10
• Presence of granulomas (suggests Crohn's disease) or decreased goblet cells (suggests autoimmune enteropathy) 8

Clinical Pitfalls and Caveats

Orientation Artifacts

• Improperly oriented biopsies cannot be accurately assessed for villus-to-crypt ratio and may lead to false-negative interpretations 1
• Request review by an experienced gastrointestinal pathologist to confirm proper orientation and evaluate for alternative diagnoses 8

Seronegative Enteropathy Confusion

• Patients with only increased IELs (≥25/100 enterocytes) and normal villi should not be considered to have seronegative enteropathy, as villous atrophy must be present for this diagnosis 8
• In combined immunodeficiency, negative celiac serology does not exclude villous atrophy from other causes 1

Sampling Error

• Villous atrophy may be patchy; obtain biopsies from both duodenal bulb and second portion of duodenum to avoid sampling error 1
• Consider capsule endoscopy if duodenal biopsies are equivocal but clinical suspicion remains high 5

Immediate Management Implications

Urgent Interventions

• Initiate aggressive fluid resuscitation with reduced-osmolarity oral rehydration solution or intravenous isotonic crystalloids depending on severity 2
• Begin broad-spectrum antimicrobial therapy immediately (third-generation cephalosporin such as ceftriaxone) when villous atrophy is identified in a severely ill immunocompromised patient 2
• Add azithromycin if bacillary dysentery features are present (frequent bloody stools, fever, abdominal cramps) 2

Foundational Immunologic Therapy

• Initiate intravenous immunoglobulin (IVIG) replacement as foundational treatment to reduce infection frequency and support immune function 2
• Refer immediately for hematopoietic stem cell transplantation (HSCT), the definitive curative option; early referral before severe infection onset is the strongest predictor of favorable outcomes 2, 11

Diagnostic Workup

• Perform comprehensive immune assessment: quantitative serum immunoglobulins (IgG, IgM, IgA), complete blood count with differential, and lymphocyte subset analysis (CD4+, CD8+, B-cell, NK-cell panels) 2
• Obtain molecular genetic testing to confirm diagnosis, enable genetic counseling, and identify eligibility for gene-specific therapies 2, 11